UniProtKB/Swiss-Prot P50440 : Variant p.Pro341Leu
Glycine amidinotransferase, mitochondrial
Gene: GATM
Feedback ?
Variant information
Variant position:
341
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LP/P [Disclaimer : Variants classification is intended for research purposes only, not for clinical and diagnostic use . The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant. ]
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Proline (P) to Leucine (L) at position 341 (P341L, p.Pro341Leu).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Similar physico-chemical property. Both residues are medium size and hydrophobic.
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
-3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Variant description:
In FRTS1; results in GATM protein aggregation; GATM deposits affect mitochondrial morphology leading to abnormal and elongated mitochondria.
Any additional useful information about the variant.
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
341
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
423
The length of the canonical sequence.
Location on the sequence:
DRPCHQIDLFKKAGWTIITP
P TPIIPDDHPLWMSSKWLSMN
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human DRPCHQIDLFKKAGWTIITPP TPIIPDDHPLWMSSKWLSMN
Mouse DRPCHQIDLFKKAGWTIVTPP TPVIPDDHPLWMSSKWLSMN
Rat DRPCHQIDLFKKAGWTIVTPP TPVIPDDHPLWMSSKWLSMN
Pig DRPCHQIDLFKKAGWTIVTPP IPVIPDDHPLWMSSKWLSMN
Bovine DRPCHQIDLFKKAGWTIVTPP TPIIPDDHPLWMSSKWLSMN
Chicken DRPCHQIELFKKAGWTVIHPP VPLIPDDHPLWMSSKWLSMN
Xenopus laevis DRPCHQIELFKKAGWTVVTPP TPLIPDNHPLWMSSKWLSMN
Xenopus tropicalis DRPCHQIELFKKAGWTVVTPP IPLIPDNHPLWMSSKWLSMN
Zebrafish DRPCRQIEMFKKAGWTVVTPP TPLIPDNHPLWMSSKWLSMN
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
44 – 423
Glycine amidinotransferase, mitochondrial
Binding site
322 – 322
Binding site
354 – 354
Binding site
355 – 355
Mutagenesis
322 – 322
R -> E. Significantly reduced activity.
Mutagenesis
355 – 355
S -> A. Significantly reduced activity.
Literature citations
Glycine amidinotransferase (GATM), renal Fanconi syndrome, and kidney failure.
Reichold M.; Klootwijk E.D.; Reinders J.; Otto E.A.; Milani M.; Broeker C.; Laing C.; Wiesner J.; Devi S.; Zhou W.; Schmitt R.; Tegtmeier I.; Sterner C.; Doellerer H.; Renner K.; Oefner P.J.; Dettmer K.; Simbuerger J.M.; Witzgall R.; Stanescu H.C.; Dumitriu S.; Iancu D.; Patel V.; Mozere M.; Tekman M.; Jaureguiberry G.; Issler N.; Kesselheim A.; Walsh S.B.; Gale D.P.; Howie A.J.; Martins J.R.; Hall A.M.; Kasgharian M.; O'Brien K.; Ferreira C.R.; Atwal P.S.; Jain M.; Hammers A.; Charles-Edwards G.; Choe C.U.; Isbrandt D.; Cebrian-Serrano A.; Davies B.; Sandford R.N.; Pugh C.; Konecki D.S.; Povey S.; Bockenhauer D.; Lichter-Konecki U.; Gahl W.A.; Unwin R.J.; Warth R.; Kleta R.;
J. Am. Soc. Nephrol. 29:1849-1858(2018)
Cited for: VARIANTS FRTS1 SER-320; ALA-336; ILE-336 AND LEU-341; INVOLVEMENT IN FRTS1; CHARACTERIZATION OF VARIANTS FRTS1 SER-320; ALA-336; ILE-336 AND LEU-341;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.